Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.56 |
| ▸ | PPARA | Q07869 | 10/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6627832 | 1.00 | PPARG (0.56) | PPARGPPARASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8669222 | 0.91 | PPARG (0.49) | PPARGPPARASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7762661 | 0.91 | PPARG (0.49) | PPARGPPARASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1859069 | 0.90 | PPARG (0.58) | PPARGPPARASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3653035 | 0.86 | SLC1A3 (0.49) | PPARGPPARASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3861924 | 0.84 | PPARG (0.68) | PPARGPPARASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL31290859 | 0.84 | PPARA (0.63) | PPARGPPARA | |
| SCHEMBL29060162 | 0.83 | SLC1A3 (0.46) | PPARGPPARASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7495011 | 0.83 | PPARG (0.61) | PPARGPPARAMEN1KMT2ASRR | |
| SCHEMBL27709333 | 0.83 | SLC1A3 (0.49) | PPARGPPARASLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064193-A1 | HETEROCYCLIC GPR40 MODULATORS | Amgen, Inc (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008030520-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
| CN-1512983-A | Compounds and compositions as cathepsins inhibitors | AXYSҩ�﹫˾ | 2004-07-14 | — | — | CN | disclosed |
| EP-1397340-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002098850-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | PPARG 1625/4885PPARA 2585/4885SLC1A3 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.